Ciclosporin opthalmic - Laboratoires TheaAlternative Names: T-1580; T1580 opthalmic- Laboratoires Thea
Latest Information Update: 12 Jul 2016
At a glance
- Originator Laboratoires Thea
- Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Dry eyes
Most Recent Events
- 17 May 2016 Phase-III clinical trials in Dry eyes (In adults, In the elderly) in Greece, Lithuania, Austria, Latvia, Hungary (Ophthalmic) (EudraCT2015-005405-36)